Ioannis Boukovinas
Overview
Explore the profile of Ioannis Boukovinas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
87
Citations
1333
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kiryttopoulos A, Evangeliou A, Katsanika I, Boukovinas I, Foroglou N, Zountsas B, et al.
Front Nutr
. 2025 Mar;
11:1489812.
PMID: 40041752
Introduction: Glioblastoma multiforme (GBM) ranks as one of the most aggressive primary malignant tumor affecting the brain. The persistent challenge of treatment failure and high relapse rates in GBM highlights...
2.
Taieb J, Souglakos J, Boukovinas I, Falcoz A, Pages F, Messaritakis I, et al.
J Clin Oncol
. 2025 Feb;
:JCO2400648.
PMID: 39903903
Purpose: Immunoscore (IS) and circulating tumor DNA (ctDNA) are two emerging technologies in improving prognostication and tailoring adjuvant treatments in patients resected from a stage III colon cancer (CC). Here,...
3.
Yu F, Ahmed F, Smilkou S, Yasmin-Karim S, Darbeheshti F, Markou A, et al.
Clin Chem
. 2024 Jul;
70(9):1151-1161.
PMID: 39039866
Background: Detection of minor DNA allele alterations is becoming increasingly important for early detection and monitoring of cancer. We describe a new method that uses ultraviolet light to eliminate wild-type...
4.
Kokkali S, Boukovinas I, de Bree E, Koumarianou A, Georgoulias V, Kyriazoglou A, et al.
Cancers (Basel)
. 2024 Jul;
16(13).
PMID: 39001377
Precise classification of sarcomas is crucial to optimal clinical management. In this prospective, multicenter, observational study within the Hellenic Group of Sarcoma and Rare Cancers (HGSRC), we assessed the effect...
5.
Gallois C, Shi Q, Pederson L, Andre T, Iveson T, Sobrero A, et al.
J Clin Oncol
. 2024 Mar;
42(19):2295-2305.
PMID: 38547438
Purpose: A number of studies suggest that older patients may have reduced or no benefit from the addition of oxaliplatin to fluoropyrimidines as adjuvant chemotherapy for stage III colon cancer...
6.
Domingo E, Kelly C, Hay J, Sansom O, Maka N, Oien K, et al.
J Clin Oncol
. 2024 Mar;
42(18):2207-2218.
PMID: 38484206
Purpose: Immunoscore (IS) is prognostic in stage III colorectal cancer (CRC) and may predict benefit of duration (6 3 months) of adjuvant infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy. We...
7.
Agelaki S, Boukovinas I, Athanasiadis I, Trimis G, Dimitriadis I, Poughias L, et al.
Cancer Med
. 2024 Jan;
13(3):e6916.
PMID: 38247106
Aims: The aim of this systematic literature review was to provide updated information on human papillomavirus (HPV) prevalence in locally and regionally advanced (LA) and recurrent/metastatic (RM) head and neck...
8.
Ziogas D, Papadopoulou E, Gogas H, Sakellariou S, Felekouras E, Theocharopoulos C, et al.
Cancers (Basel)
. 2024 Jan;
16(1).
PMID: 38201431
Despite ongoing oncological advances, pancreatic ductal adenocarcinoma (PDAC) continues to have an extremely poor prognosis with limited targeted and immunotherapeutic options. Its genomic background has not been fully characterized yet...
9.
Bafaloukos D, Kouzis P, Gouveris P, Boukovinas I, Kalbakis K, Baka S, et al.
Melanoma Res
. 2023 Dec;
34(2):152-165.
PMID: 38092014
This study primarily aimed to generate real-world evidence (RWE) on the profile and first-line treatment (1LT) patterns of patients with advanced (unresectable Stage III/metastatic) cutaneous melanoma initiated on immuno-oncology (IO)-...
10.
Tsantikidi A, Papadopoulou E, Metaxa-Mariatou V, Kapetsis G, Tsaousis G, Meintani A, et al.
Diagnostics (Basel)
. 2023 Sep;
13(18).
PMID: 37761329
Several tumor types have been efficiently treated with PARP inhibitors (PARPis), which are now approved for the treatment of ovarian, breast, prostate, and pancreatic cancers. The genes and mutations in...